CNAT Conatus Pharmaceuticals Inc.

0.32
0  -1%
Previous Close 0.33
Open 0.33
Price To Book 0.45
Market Cap 10,632,738
Shares 33,165,122
Volume 201,693
Short Ratio
Av. Daily Volume 978,864

NewsSee all news

  1. Conatus (CNAT) Stock Price Could Hit Zero
  2. Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
  3. The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart
  4. Conatus' Emricasan Lags Primary Goal in Liver Function Study
  5. NASH Disappointment Forces Conatus To Explore Strategic Alternatives

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data June 24, 2019 did not meet primary endpoint.
Emricasan
NASH cirrhosis - ENCORE-LF trial
Phase 2b data released December 5, 2018 did not meet primary endpoint. 48-week liver function data due mid-2019.
Emricasan
NASH cirrhosis - ENCORE-PH trial
Phase 2 topline data released Jan 2015
Emricasan
Acute-on-Chronic Liver Failure (ACLF)
Phase 2b data released April 4, 2018. Primary endpoint not met.
Emricasan
Liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT)
Phase 2b trial did not meet primary endpoint - March 21, 2019.
Emricasan
NASH fibrosis - ENCORE-NF trial
Phase 2 topline data released early January 2016
Emricasan
Liver Cirrhosis
Phase 2 data released September 2015.
Emricasan
Portal Hypertension

Latest News

  1. Conatus (CNAT) Stock Price Could Hit Zero
  2. Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
  3. The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart
  4. Conatus' Emricasan Lags Primary Goal in Liver Function Study
  5. NASH Disappointment Forces Conatus To Explore Strategic Alternatives
  6. UPDATE 1-Conatus Pharma to explore options as liver disease drug fails trial
  7. Conatus to Explore Strategic Alternatives and Implement Restructuring Plan
  8. Conatus Announces Results from ENCORE-LF and ENCORE-PH Phase 2b Clinical Trials in NASH Cirrhosis
  9. CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
  10. Conatus (CNAT) Down 5.8% Since Last Earnings Report: Can It Rebound?
  11. Conatus Down More Than 60% in the Past 90 Days: Here's Why
  12. How Many Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Shares Do Institutions Own?
  13. Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1
  14. Conatus Pharmaceuticals (CNAT) Reports Q1 Loss, Lags Revenue Estimates
  15. Conatus: 1Q Earnings Snapshot
  16. Conatus Pharmaceuticals Announces Publication Demonstrating that Emricasan Ameliorates Portal Hypertension, Improves Liver Structure and Function in a Preclinical Model of Advanced Cirrhosis
  17. Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
  18. Conatus Late-breaker Oral Presentation at EASL Meeting Details Results of ENCORE-PH Phase 2b Clinical Trial in Patients with NASH Cirrhosis and Severe Portal Hypertension
  19. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts
  20. Why Is Conatus (CNAT) Down 37.8% Since Last Earnings Report?